Long-term follow-up for CS-101 recipients
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study follows up on people who have already received the CS-101 infusion in a previous trial. It aims to check how participants are doing over time. There are no restrictions to join if you already received CS-101.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already received the CS-101 infusion in a past study.
- You (or your legal guardian or representative) must sign a consent form agreeing to join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows up with people who already received the CS-101 injection in a previous trial to check its safety and how well it works over time.
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
This trial tests a new drug, 9MW3011, in people with a type of beta-thalassemia that does not require regular blood transfusions. The goal is to see if the drug can safely help manage iron overload and improve hemoglobin levels.
This study checks on participants who previously received the experimental treatment CS-101. It aims to track their health over time to see how safe and effective the treatment is in the long run.
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
This study is for people with beta-thalassemia who have already received the gene therapy betibeglogene autotemcel (beti-cel). It collects information to learn how patients are doing after this treatment in real-world settings.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.